©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 16, 2021; 9(20): 5398-5407
Published online Jul 16, 2021. doi: 10.12998/wjcc.v9.i20.5398
Published online Jul 16, 2021. doi: 10.12998/wjcc.v9.i20.5398
Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy
Danko Mikulic, Department of Surgery, University Hospital Merkur, Zagreb 10000, Croatia
Anna Mrzljak, Department of Gastroenterology and Hepatology, University Hospital Center Zagreb, Zagreb 10000, Croatia
Author contributions: Mikulic D and Mrzljak A made contributions to the conception and design of the study, collecting of data and in drafting and revising the manuscript; both authors read and approved the final manuscript.
Conflict-of-interest statement: The authors have any conflict of interest to declare.
Corresponding author: Danko Mikulic, FEBS, MD, PhD, Surgeon, Department of Surgery, University Hospital Merkur, Zajceva 19, Zagreb 10000, Croatia. danko.mikulic@zg.t-com.hr
Received: January 27, 2021
Peer-review started: January 27, 2021
First decision: February 25, 2021
Revised: March 1, 2021
Accepted: May 27, 2021
Article in press: May 27, 2021
Published online: July 16, 2021
Processing time: 161 Days and 2.2 Hours
Peer-review started: January 27, 2021
First decision: February 25, 2021
Revised: March 1, 2021
Accepted: May 27, 2021
Article in press: May 27, 2021
Published online: July 16, 2021
Processing time: 161 Days and 2.2 Hours
Core Tip
Core Tip: Curative treatment of pancreatic ductal adenocarcinoma is only possible after margin negative surgical resection. Borderline resectable pancreatic cancer is characterized by vascular tumor involvement and the need to perform vascular resection to achieve radical resection. This report reviewed the characteristics of borderline resectable pancreatic cancer and the current treatment perspectives, including aggressive surgical approaches in the era of neoadjuvant therapy.